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Abstract
Background: Stromal tumor-infiltrating lymphocytes (TILs) are a robust prognostic factor in triple-negative breast
cancer (TNBC). However, the clinical significance of TILs may be influenced by the complex landscape of the tumor
immune microenvironment. In this study, we aimed to evaluate the composition and the functionality of
lymphocytic infiltration and checkpoint receptors in TNBC.
Methods: Formalin-fixed, paraffin-embedded tissues were retrospectively collected from a cohort of patients with
early-stage TNBC treated with adjuvant anthracycline-based chemotherapy (n = 259). Results were validated in an
independent cohort of patients with TNBC (n = 104). Stromal TILs were evaluated on hematoxylin-and-eosin-stained
sections. The density of CD4+, CD8+, and FOXP3+ lymphocytes, and the expression of the immune checkpoints
PD-1 and LAG-3, were assessed by immunohistochemical analysis.
Results: The presence of elevated TILs positively correlated with the density of all T cell subtypes, especially
cytotoxic CD8+ lymphocytes. We showed that increasing stromal TILs assessed as a continuous variable is an
independent prognostic marker of prolonged relapse-free survival and overall survival in TNBC. Among immune
subpopulations, CD8+ lymphocytes are the main effectors of anti-tumor immune responses. In two independent
cohorts, we found that PD-1 and LAG-3 were concurrently expressed in approximately 15% of patients with TNBC.
The expression of both checkpoint receptors positively correlated with the presence of TILs, but was not
significantly associated with patient outcome.
Conclusions: Overall, our data indicate that the evaluation of stromal TILs remains the most reliable immune
prognostic marker in TNBC, and support the clinical evaluation of anti-PD-1/PD-L1 and anti-LAG-3 in a subset of
patients with TNBC who have concurrent expression of both checkpoint receptors.
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Background
Triple-negative breast cancer (TNBC) is usually charac-
terized by an aggressive phenotype, associated with an
increased risk of early recurrence within 3 years after
diagnosis, and poor prognosis [1]. Current treatment
approaches are limited to cytotoxic chemotherapy due
to the lack of specific therapeutic targets [1]. Therefore,
the identification of reliable prognostic markers and
novel therapeutic targets may allow a better stratification
of patients with TNBC, and provide the rationale for
investigating innovative treatment strategies.
Recent evidence indicates that the immune micro-
environment plays a key role in cancer progression and
response to therapies [2]. Notably, the presence of
tumor-infiltrating lymphocytes (TILs) is emerging as an
important predictor of outcome and response to chemo-
therapy in TNBC [3–7]. However, the composition of
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the tumor immune microenvironment is very heteroge-
neous, and the functional significance of specific im-
mune cell subpopulations remains poorly understood.
Indeed, cytotoxic CD8+ T cells have been shown to be
an independent favorable prognostic factor, while studies
on CD4+ T helper and forkhead box protein 3 (FOXP3)
+ T regulatory cells have shown conflicting results [8].
Furthermore, even though TILs are able to identify
and eliminate malignant cells, tumors have developed
multiple mechanisms to maintain an immunosuppres-
sive microenvironment, including the upregulation of
inhibitory receptors, such as programmed cell death 1
(PD-1) and lymphocyte activation gene 3 (LAG-3) [9].
Recent findings demonstrate that the expression of
immune markers related to immunosuppression is
enriched in triple-negative/basal-like breast cancer, and
correlate with prognosis and response to chemotherapy,
supporting the evaluation of immunotherapy in TNBC
[6, 10–14]. Thus, a deeper understanding of the com-
position and the functionality of lymphocytic infiltra-
tion could be useful to predict patients’ outcome, and
to select patients with TNBC who may benefit from
the addition of immune checkpoint drugs to standard
chemotherapeutic regimens. The aim of the present
study was to evaluate the composition and the
functionality of lymphocytic infiltration in early-stage
TNBC.
Methods
Patient cohorts and tumor samples
Formalin-fixed, paraffin-embedded (FFPE) tissues were
retrospectively collected from 259 patients who under-
went surgery at Humanitas Clinical and Research Insti-
tute (Rozzano - Milan, Italy). An additional independent
cohort of TNBC samples (n = 104) collected from
Humanitas Institutes (Catania and Castellanza, Italy)
was used. All patients had histologically confirmed inva-
sive ductal TNBC, and were treated with adjuvant
anthracycline-based chemotherapy. The study was
approved by the ethical committee of the Humanitas
Hospitals. The study was conducted according to the
“reporting of tumor marker studies” (REMARK) guide-
lines [15]. Clinical characteristics of patients included in
this study are presented in Additional file 1: Table S1.
Pathologic evaluation of TILs, immunohistochemical
analysis and scoring
Histopathologic analysis of stromal lymphocytic infiltra-
tion was performed on full-face hematoxylin and eosin
(HE)-stained sections according to Salgado et al. [16].
Stromal TILs were defined as the percentage of tumor
stroma containing infiltrating lymphocytes. Areas of
adjacent normal breast, in situ carcinoma, necrosis or fi-
brosis were not included in the evaluation. TILs were
reported in 10% increments [3, 5]. We defined the
lymphocyte-predominant breast cancer (LPBC) as TNBC
with ≥50% infiltration of either tumor stroma or tumor
nest. A binary cutoff ≥20% was also used to assess its
potential to identify low-risk patients with TNBC strati-
fied by nodal status, as previously described [17].
FFPE sections (3 μm) from TNBC samples were
deparaffinized with xylene, rehydrated with a graded
ethanol series (100%, 95%, 70%) to distilled water
according to standard immunohistochemical protocols.
Specificity of staining was determined by immunohisto-
chemistry (IHC) on a set of cultured cell pellet blocks,
normal specimens, and diverse tumor tissues in the form
of whole sections, processed using the same fixative and
processing methods as TNBC samples tested in the
study [18–20]. The optimal concentration of each anti-
body was established performing serial titrations on ser-
ial FFPE sections. Antigen-retrieval conditions and
detection methods were also optimized for each anti-
body to improve sensitivity and signal-to-noise ratio.
Specificity was further determined by western blotting.
Reproducibility of antibodies was assessed with IHC
analysis of serial FFPE sections stained under the same
conditions on different days [20]. Briefly, heat-induced
antigen retrieval was performed by placing slides in Tris-
EDTA (pH9) or citrate (pH6) buffer for 20 minutes at 98 °
C using a water bath. Tissue sections were cooled in buf-
fer for 20 minutes before the treatment with Peroxidase
Blocking Reagent (Dako) for 10 minutes. Slides were then
incubated with Background Sniper (Biocare) for 20 -
minutes, and then with anti-CD4 (1:100, clone 4B12,
Dako), anti-CD8 (1:100, clone C8/144B, Dako), anti-
FOXP3 (1:100, clone 236A/E7, Abcam), anti-PD-1 (1:100,
clone NAT105, Abcam), and anti-LAG-3 (1:200, clone
17B4, LS Bio) primary monoclonal antibodies. After wash-
ing in PBS, DAKO Envision systems (Dako) or MACH 1
Universal HRP Polymer (BioCare), and diaminobenzidine
(DAB; BioCare) were used for chromogenic immunode-
tection, followed by counterstaining with hematoxylin.
Negative control slides without primary antibody and
positive controls for each marker were used for each
immunostaining run. Full details on IHC protocols are
provided in Additional file 1: Table S2.
IHC scoring was carried out as previously described
[21, 22]. Briefly, each section was reviewed at low
magnification. Positive lymphocytes in tumor stroma
were counted in three high power fields (HPF; ×40;
Olympus BX53), which represent the spectrum of stain-
ing seen on initial overview of the whole section, and
displayed as average number of stained cells per HPF
[21]. Patients were divided into two groups by the me-
dian value of CD4, CD8, and FOXP3 expression on TILs
for statistical analyses. Patients with ≥5% of TILs ex-
pressing PD-1 or LAG-3 were considered positive [22].
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Evaluation of TILs and IHC scoring were independ-
ently performed by two pathologists, who were blinded
for patient characteristics and outcome. The mean value
of two assessments was used for the current analyses.
Agreement between the two pathologists was measured
by calculating Cohen's kappa and the interclass correl-
ation coefficients (ICCs). The inter-observer κ value for
the categorical parameter LPBC was 0.63. The ICCs
were 0.79 for TILs assessed as a continuous variable,
0.82 for CD4, 0.84 for CD8, 0.76 for FOXP3, 0.79 for
PD-1, and 0.78 for LAG-3.
Statistical analysis
Clinicopathological associations were tested using Fish-
er’s exact test and the Mann–Whitney U test for cat-
egorical and continuous data, respectively. Pearson
correlation analysis was performed to evaluate the cor-
relation between variables. Patients who developed
tumor recurrence within 36 months after primary sur-
gery were considered positive for tumor relapse, whereas
patients who remained free of recurrence for the same
time frame were defined as having non-relapsing tumors.
Relapse-free survival (RFS) was defined as the time from
surgery until the detection of distant recurrence. Overall
survival (OS) was defined as the time from surgery to
date of death. Patients who were alive (for OS) or
recurrence-free (for RFS) were censored at date of last
follow up. Survival analyses were performed by the Cox
univariate proportional hazards model. For visualization
purposes, Kaplan–Meier analyses were used for the sur-
vival curves test (Mantel-Cox log-rank test). Forest plots
were used to visualize the results of Cox univariate ana-
lysis for RFS and OS. Multivariate Cox proportional haz-
ard regression analysis was adjusted for relevant clinical
covariates, including age at diagnosis, histologic grade,
lymph node status, tumor size, and tumor stage. The
likelihood ratio (LR) test was used to compare the differ-
ent prognostic models. Changes in the LR values
(ΔLRχ2) were used to quantitatively measure the relative
amount of prognostic information of one model com-
pared with another. All tests were two-sided and the
level of statistical significance was set at P <0.05. Statis-
tical analyses were performed using GraphPad Prism
version 5, and StatsDirect version 3.
Results
Phenotypic profiling of TILs in TNBC
The majority of TNBC samples had lymphocytic infiltra-
tion in tumor stroma. Approximately 75% of patients
with TNBC had at least 10% of stromal TILs (range 10–
80%), while only 25% had virtual absence of lymphocytes
(range 0–1%). The LPBC (TILs ≥50%) phenotype was
found in 10.8% of patients with TNBC.
We further explored the nature of immune infiltrates
by performing IHC of the main lymphocyte subsets.
Immunophenotypic characterization of lymphocyte
components showed that the presence of elevated
TILs was positively associated with the density of CD4+
(r = 0.347) and FOXP3+ (r = 0.327) lymphocytes, and
the strongest correlation was with CD8+ T cells (r = 0.511;
Fig. 1a). These results were confirmed by analyzing an
additional cohort of patients with TNBC (n = 104; Fig. 1b,
Additional file 1: Table S1). Representative images of
TNBC with different degrees of TILs and distinct
lymphocyte subpopulations are depicted in Fig. 1c-f.
Association of TILs with clinicopathological parameters
and survival in TNBC
A lower stromal TILs content was associated with larger
tumor size (P = 1.8E-02; Additional file 1: Table S3).
There were no other significant associations between the
variables examined and the presence of TILs, or with
different immune cell subsets in a first TNBC cohort
(n = 259; Additional file 1: Table S3). The data were
confirmed in the validation cohort of TNBC (n = 104;
Additional file 1: Table S4).
The association of LPBC, continuous TIL scores, and
single immune components with RFS or OS in patients
with TNBC was evaluated by Cox proportional hazard
regression analyses (Fig. 2, Fig. 3, and Table 1). TILs
assessed as a binary variable (LPBC vs non-LPBC) were
associated with both RFS (hazard ratio (HR) = 0.22; 95%
confidence interval (CI), 005 to 0.88; P = 3.28E-02) and
OS (HR = 0.29; 95% CI, 0.09 to 0.93; P = 3.73E-02) in
TNBC in univariate analysis (Fig. 2 and Fig. 3a), but had
no prognostic value on multivariate analysis (Table 1).
However, continuous TIL scores had a significant prog-
nostic value for RFS (HR = 0.92; 95% CI, 0.82 to 0.98; P
< 1.00E-04) and OS (HR = 0.92; 95% CI, 0.89 to 0.95; P <
1.00E-04) in TNBC (Fig. 2 and Fig. 3b). Cox multivariate
analysis confirmed that TIL scores were independently
associated with RFS (HR = 0.93; 95% CI, 0.89 to 0.96;
P = 1.00E-04) and OS (HR = 0.93; 95% CI, 0.90 to 0.95;
P = 1.00E-04) in TNBC (Table 1). Furthermore, con-
tinuous TIL scores added significant prognostic infor-
mation for RFS (ΔLRχ2 = 31.35; P < 1.00E-04) and OS
(ΔLRχ2 = 28.23; P < 1.00E-04) beyond that provided by
standard clinicopathological variables (Table 2).
Given that recent data suggest that a stromal TIL
value ≥20% in early-stage TNBC could identify patients
with good outcome across nodal categories, we
performed Kaplan–Meier analysis to evaluate the prog-
nostic value of this cutoff in TNBC stratified by nodal
status (lymph node-negative and lymph node-positive)
[17]. Overall, we found that patients with high levels of
TILs (≥20%) had a better outcome compared with those
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with low TILs (<20%) in both nodal categories
(Additional file 2: Figure S1).
Among lymphocyte subsets, the density of CD4+ cells
was not significantly prognostic in TNBC (Fig. 2), while
CD8+ lymphocytes were consistently associated with
prolonged RFS and OS in both univariate (HR = 0.54;
95% CI, 0.33 to 0.91; P = 2.05E-02 for RFS; HR = 0.54;
95% CI, 0.32 to 0.91; P = 2.07E-02 for OS) and multivari-
ate analysis (HR = 0.58; 95% CI, 0.34 to 0.97; P = 3.72E-
02 for RFS; HR = 0.58; 95%CI, 0.34 to 0.97; P = 3.88E-02
for OS), indicating that cytotoxic CD8+ T lymphocytes
are the main effectors of anti-tumor immune responses
(Fig. 2, Fig. 3c, and Table 1). Furthermore, high FOXP3+
cells were also significantly associated with better
Fig. 2 Univariate Cox regression analysis of tumor-infiltrating lymphocytes (TILs), immune markers and checkpoint receptors for relapse-free survival
and overall survival in triple-negative breast cancer. Forest plot of hazard ratios (HR) with 95% confidence intervals (CI) for relapse-free survival (a) and
overall survival (b), for lymphocyte-predominant breast cancer (LPBC) (cutoff value ≥50%), TIL scores (treated as a continuous variable for each 10%
increment), immune markers (CD4, CD8, and forkhead box protein 3 (FOXP3); median values were used as the cutoff), and immune checkpoints
(programmed cell death 1 (PD-1), and lymphocyte activation gene 3 (LAG-3); a cutoff value ≥5% was used)
Fig. 1 Distribution of tumor-infiltrating lymphocytes (TILs) and immune cell subpopulations in triple-negative breast cancer (TNBC). Immunophenotypic
characterization of lymphocyte components showed that the presence of elevated TILs positively correlated with the density of CD4+, CD8+,
and forkhead box protein 3 (FOXP3+) lymphocytes in TNBC in the discovery (a) and the validation (b) cohorts. Pearson’s correlation coefficients
(r) for each cell subpopulation are shown. Cell density was scored by determining the average number of stained cells in three distinct high power
fields (HPF). c-f Representative images of hematoxylin and eosin sections from TNBC samples with high (c) and low (d) TIL scores. Representative
immunohistochemical staining of CD4, CD8, and FOXP3 in serial sections of TNBC specimens with high (e) and low (f) lymphocytic infiltration. Scale
bars represent 50 μm
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survival in univariate (HR = 0.56; 95% CI, 0.33 to 0.95;
P = 3.31E-02 for RFS; HR = 0.58; 95% CI, 0.34 to 0.99;
P = 4.73E-02 for OS) and multivariate analysis (HR = 0.52;
95% CI, 0.31 to 0.89; P = 1.71E-02 for RFS; HR = 0.55; 95%
CI, 0.32 to 0.94; P = 2.90E-02 for OS; Fig. 2, Fig. 3d, and
Table 1). However, FOXP3+ cells were consistently associ-
ated with the density of CD8+ lymphocytes (r = 0.716), and
the presence of FOXP3+ TILs was prognostically insignifi-
cant in TNBC stratified by the presence or absence of CD8
+ cells (Additional file 1: Table S5).
Interestingly, we found that the infiltration of FOXP3
+ cells tended to be associated with reduced survival in
TNBC with low numbers of CD8+ lymphocytes
(Additional file 1: Table S5), suggesting that the prog-
nostic value of FOXP3+ cells was highly dependent on
the concurrent presence of cytotoxic T lymphocytes. Of
note, neither CD8+ nor FOXP3+ cells added consistent
prognostic value for RFS (ΔLRχ2 = 0.43; P = 5.12E-01
for CD8; ΔLRχ2 = 1.02; P = 3.12E-01 for FOXP3) and
OS (ΔLRχ2 = 0.50; P = 4.79E-01 for CD8; ΔLRχ2 = 0.99;
Fig. 3 Prognostic value of stromal tumor-infiltrating lymphocytes (TILs) and immune cell subpopulations in triple-negative breast cancer.
Kaplan–Meier curves of relapse-free survival and overall survival for binary lymphocyte-predominant breast cancer (LPBC) (cutoff value ≥50%) (a),
continuous stromal TILs (grouped as 0 (range 0–1%) vs 10 (range 2–10%) vs 20–40 (range 11– 40%) vs 50–80 (range 41–80%)) (b), CD8 (median
value) (c), and forkhead box protein 3 (FOXP3) (median value) (d). Curves were compared using the log-rank test
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P = 3.20E-01 for FOXP3) beyond that provided by the
TIL score in the multivariate model (Table 2), suggest-
ing that the evaluation of single immune components
may not be as informative as the global evaluation of
stromal TILs.
Evaluation of the clinical relevance of immune
checkpoints in TNBC
To assess the functional status of TILs in TNBC, we an-
alyzed the expression of the checkpoint receptors PD-1
and LAG-3 by IHC. PD-1+ and LAG-3+ TILs were
Table 1 Multivariate Cox regression analysis of tumor-infiltrating lymphocytes and immune markers for relapse-free survival and
overall survival in triple-negative breast cancer
Relapse-free survival Overall survival
Variable HR 95% CI P value HR 95% CI P value
LPBC 0.24 0.06–1.00 5.10E-02 0.32 0.10–1.03 5.60E-02
Age 1.09 0.66–1.80 7.28E-01 1.13 0.68–1.87 6.27E-01
Histologic grade 1.66 0.78–3.53 1.91E-01 1.85 0.87–3.94 1.09E-01
Nodal status 3.44 1.72–6.88 5.00E-04 3.19 1.59–6.39 1.00E-03
Tumor size 1.21 0.74–1.99 4.48E-01 1.27 0.77–2.09 3.48E-01
Tumor stage 1.34 0.76–2.35 3.12E-01 1.38 0.78–2.43 2.69E-01
TILsa 0.93 0.89–0.96 1.00E-04 0.93 0.90–0.95 1.00E-04
Age 0.97 0.58–1.61 8.97E-01 1.02 0.61–1.71 9.32E-01
Histologic grade 1.34 0.63–2.87 4.48E-01 1.76 0.83–3.75 1.40E-01
Nodal status 2.91 1.43–5.90 3.10E-03 2.59 1.27–5.28 8.70E-03
Tumor size 1.11 0.68–1.83 6.70E-01 1.15 0.70–1.90 5.73E-01
Tumor stage 1.46 0.82–2.62 2.00E-01 1.45 0.80–2.63 2.19E-01
CD8 0.58 0.34–0.97 3.72E-02 0.58 0.34–0.97 3.88E-02
Age 1.12 0.68–1.85 6.66E-01 1.16 0.70–1.93 5.58E-01
Histologic grade 1.71 0.80–3.65 1.67E-01 1.91 0.90–4.08 9.34E-02
Nodal status 3.46 1.73–6.90 4.00E-04 3.23 1.62–6.45 9.00E-04
Tumor size 1.20 0.73–1.97 4.80E-01 1.26 0.76–2.07 3.70E-01
Tumor stage 1.35 0.76–2.37 3.01E-01 1.35 0.76–2.40 2.99E-01
FOXP3 0.52 0.31–0.89 1.71E-02 0.55 0.32–0.94 2.90E-02
Age 1.10 0.67–1.83 6.98E-01 1.16 0.70–1.92 5.70E-01
Histologic grade 1.81 0.84–3.87 1.28E-01 2.01 0.94–4.30 7.27E-02
Nodal status 3.54 1.79–7.00 3.00E-04 3.30 1.67–6.53 6.00E-04
Tumor size 1.23 0.75–2.03 4.05 E-01 1.30 0.79–2.13 3.06E-01
Tumor stage 1.37 0.79–2.41 2.65E-01 1.38 0.78–2.42 2.66E-01
Multivariate analysis adjusted for age (≥50 vs <5 years), histologic grade (III vs – I-II), nodal status (1 vs 0), tumor size (>20 mm vs ≤20 mm), and tumor stage
(III vs I–II). Significant P values are in italics. aTreated as a continuous variable for each 10% increment. CI confidence interval, HR hazard ratio, LPBC
lymphocyte-predominant breast cancer, TILs tumor-infiltrating lymphocytes
Table 2 Comparisons of added prognostic information
Relapse-free survival Overall survival
Variable ΔLRχ2 P value ΔLRχ2 P value
CP + TIL score vs CP 31.35 <1.00E-04 28.23 <1.00E-04
CP + LPBC vs CP 5.20 2.26E-02 4.97 2.58E-02
CP + TIL score + CD8 vs CP + TIL score 0.43 5.12E-01 0.50 4.79E-01
CP + TIL score + FOXP3 vs CP + TIL score 1.02 3.12E-01 0.99 3.20E-01
CP + TIL score + CD8 + FOXP3 vs CP + TIL score 1.82 4.02E-01 1.70 4.27E-01
Significant P values are given in italics. CP clinicopathological variables (age, histologic grade, nodal status, tumor size, and tumor stage), LPBC
lymphocyte-predominant breast cancer, LR likelihood ratio, TILs tumor-infiltrating lymphocytes, FOXP3 forkhead box protein 3
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present in approximately 30% and 18% of patients with
TNBC, respectively (Fig. 4a, b). Concurrent expression
of both immune checkpoints was observed in 15.4% of
TNBC cases. We found that the expression of both PD-
1 and LAG-3 positively correlated with the presence of
TILs (r = 0.511; r = 0.576, respectively), particularly with
CD8+ cells (r = 0.568; r = 0.490, respectively; Additional
file 2: Figure S2a). By analyzing an additional cohort of
patients with TNBC (n = 104; Additional file 1: Table
S1), we confirmed that PD-1 and LAG-3 were concur-
rently expressed in 13.5% of patients, and that their
expression was positively associated with TILs (r = 0.438;
r = 0.537, respectively), and with CD8+ cells (r = 0.495; r
= 0.467, respectively; Additional file 2: Figure S2b). Even
though a trend for longer RFS was observed in univari-
ate analysis, the presence of both PD-1+ and LAG-3+
TILs had no significant prognostic value in the discovery
dataset (Fig. 2).
Discussion
Recent evidence suggests that the presence of TILs is an
important predictor of outcome and response to chemo-
therapy in TNBC [3–7]. In this dataset, we confirmed
that increasing stromal TILs is an independent prognos-
tic marker for prolonged RFS and OS in TNBC treated
with adjuvant anthracycline-based chemotherapy. Stud-
ies evaluating the association between LPBC and
survival have reported conflicting results [3–7]. Indeed,
LPBC was not significantly associated with prognosis,
likely due to the reduced number of events, and the
small proportion of TNBC displaying this phenotype.
Thus, further efforts are needed to improve the
quantitative pathological assessment of TILs on HE-
stained slides.
In agreement with recent data, we demonstrated that a
value of ≥20% of stromal TILs could identify a group of
low-risk patients with both lymph node-negative and
lymph node-positive early-stage TNBC [17]. Further-
more, our findings suggest that patients with low
numbers of TILs may benefit from the generation of an
anti-tumor immune response, while boosting the
lymphocyte activity (e.g. checkpoint inhibitors) might
prove useful in patients with high numbers of TILs,
associated with higher disease burden.
Although the presence of TILs reflects the activation
of a local anti-tumor immune response, distinct immune
cell subpopulations may have specific biological signifi-
cance. In agreement with previous findings, we demon-
strated that both CD8+ and FOXP3+ cells were
associated with good outcome in patients with TNBC,
and that the clinical significance of FOXP3+ lympho-
cytes was highly dependent on the concurrent presence
of cytotoxic T cells [23–27]. Interestingly, when stratified
based on the presence of CD8+ lymphocytes, a high in-
filtration of FOXP3+ cells trended towards reduced sur-
vival in TNBC patients with low numbers of CD8+ cells.
These results suggest that CD8+ lymphocytes could be
the main effectors of anti-tumor immune responses, and
that the consistent correlation between FOXP3 positivity
and cytotoxic lymphocytes may in part explain conflict-
ing results reported in previous studies [8].
Overall, our findings indicate that the assessment of
single immune components may not be as informative
as the global evaluation of stromal TILs. However, the
Fig. 4 Programmed cell death 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) protein expression in triple-negative breast cancer (TNBC).
Representative immunohistochemical staining of PD-1 and LAG-3 in serial sections of TNBC samples with high (a) and low (b) lymphocytic
infiltration. Scale bars represent 50 μm
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understanding of the biological role of different lympho-
cyte subpopulations warrants further investigations, and
could be useful in selecting patients with TNBC who
may benefit from the addition of specific immunomodu-
latory therapies to conventional chemotherapeutic
regimens.
Even though TILs are emerging as important prognos-
tic and predictive factors in TNBC, it is worth noting
that many TNBC have few TILs, and even in the
presence of massive lymphocytic infiltration, immuno-
suppressive mechanisms should be considered [28]. In
this scenario, both radiotherapy and chemotherapeutic
agents (e.g. anthracyclines) have been shown in preclin-
ical models to be able to shape the tumor microenviron-
ment, and to boost an effective immune response
against tumor cells [29, 30]. These therapies could be
rationally evaluated in combination with immunomodu-
latory drugs to synergize with pre-existing lymphocytes
with tumoricidal activity, or to elicit a de novo local
immune response in tumors lacking TILs.
Even though the immune system can recognize and
eliminate malignant cells, tumors have developed mul-
tiple mechanisms to evade effective immunosurveillance,
including the activation of the immune checkpoints PD-
1 and LAG-3 [2, 9]. We demonstrated that PD-1+ and
LAG-3+ TILs were present in approximately 30% and
18% of TNBCs, respectively, and that their presence in
the tumor microenvironment tended to be associated
with good prognosis in TNBC. The upregulation of
these receptors, especially PD-1, has been classically
described as a prominent immune resistance mechan-
ism, and analyses performed on tissue microarrays have
revealed an inverse correlation with outcome in patients
with breast cancer [9, 31]. Indeed, double-positive PD-1/
LAG-3 TILs have been recently demonstrated to show a
more exhausted phenotype and functionality compared
with single-positive or negative TILs in a preclinical
model, likely leading to increased cancer immune eva-
sion [32]. However, the role of co-inhibitory molecules
in the modulation of the tumor immune microenviron-
ment, and the mechanisms underlying T cell exhaustion
and anergy are still poorly understood [9, 33]. Further-
more, it is worth noting that the activity of immune cells
depends on the interaction with cancer cells, and recent
findings support the idea that the functional relevance of
checkpoint proteins is highly sensitive to the context
(e.g. amount of antigen, topographical relationships with
tumor cells and PD-L1-expressing cells) [9, 34]. Conse-
quently, the evaluation of the clinical and biological sig-
nificance of immune markers, especially those reflecting
the activation status of lymphocytes, should be per-
formed on whole tissue sections, reducing sampling bias
due to tumor heterogeneity, and providing a more com-
prehensive understanding of the complex tumor-
immune dynamics. Moreover, we found that the expres-
sion of both PD-1 and LAG-3 highly correlated with the
presence of TILs, especially cytotoxic CD8+ cells.
Even though stratified analysis according to levels of
lymphocytic infiltration was not performed due to the low
number of cases in each subgroup, our results suggest that
the presence of PD-1+ and LAG-3+ TILs in the tumor
microenvironment may reflect the occurrence of an active,
although partially exhausted, intratumoral immune
response, rather than representing a global marker of im-
munosuppression. Accordingly, emerging evidence have
revealed that local immunomodulatory factors (e.g. IFN-γ
released by TILs), or the activation of oncogenic signaling
pathways (e.g. the PI3K pathway) can promote the expres-
sion of PD-L1, which has been shown to be enriched in
triple-negative/basal-like breast cancer, and to be associ-
ated with good outcome and response to chemotherapy in
patients with TNBC [6, 10–14].
Interestingly, by analyzing two independent cohorts,
we found that PD-1+ and LAG-3+ TILs were concur-
rently expressed in approximately 15% of TNBC cases.
Thus, reversing the phenotype of exhausted T lympho-
cytes by targeting multiple inhibitory receptors may
boost an effective anti-tumor immune response, and
represent a novel valuable strategy to treat a subgroup of
patients with TNBC. Recently, the blockade of the PD-1/
PD-L1 pathway has shown promising clinical activity in
patients with metastatic TNBC, although molecular
preselection of the candidate patients for novel clinical
trials would be valuable [33, 35–38]. Preclinical data
demonstrates that anti-LAG-3 is mildly effective as
monotherapy, but potently synergizes with anti-PD-1,
suggesting that the combined immune checkpoint inhib-
ition could enhance T cell activity and improve anti-
tumor immunity [32]. Furthermore, the dual blockade of
PD-1 and LAG-3 may exhibit less immune toxicity than
that observed with the blockade of other immune recep-
tors (e.g. CTLA-4).
Even though we confirmed the prognostic value of
TILs in TNBC, the biological link between FOXP3+ and
CD8+ lymphocytes, and the clinical relevance of check-
point receptors in patients with TNBC with different
levels of TILs, warrant further investigations. Despite
these potential limitations, our findings support the clin-
ical evaluation of combination immunotherapies with
anti-PD-1/PD-L1 and anti-LAG-3 in a specific subset of
patients with TNBC who have concurrent expression of
both checkpoints.
Conclusions
The presence of elevated TILs positively correlated with
the density of all main T cell subtypes. The assessment
of single immune components does not significantly im-
prove risk stratification given by increasing stromal
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TILs, which remains an independent prognostic marker
for TNBC treated with adjuvant chemotherapy contain-
ing anthracyclines. We have further demonstrated that
the immune checkpoints PD-1 and LAG-3 are concur-
rently expressed in nearly 15% of tumors. The expres-
sion of PD-1 and LAG-3 is highly correlated with the
presence of TILs, especially cytotoxic CD8+ cells,
reflecting the occurrence of an effective intratumoral im-
mune response. This study highlights the importance of
different lymphocyte subpopulations for the selection of
patients with primary TNBC who may benefit from
immunomodulatory drugs. Our data support a clinical
evaluation of anti-PD-1/PD-L1 and LAG-3 in combin-
ation with chemotherapy in a specific subset of patients
with TNBC.
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